Clovis Oncology Inc. [NASDAQ: CLVS] price surged by 5.55 percent to reach at $0.04. The company report on June 6, 2022 that Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
First presentation of data from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) to be presented as a late-breaking, oral abstract at the 2022 ASCO Annual Meeting and published simultaneously in the Journal of Clinical Oncology (JCO).
The ATHENA-MONO trial met its primary endpoint, showing Rubraca monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT).
A sum of 6797872 shares traded at recent session while its average daily volume was at 12.04M shares. Clovis Oncology Inc. shares reached a high of $0.73 and dropped to a low of $0.581 until finishing in the latest session at $0.70.
The one-year CLVS stock forecast points to a potential upside of 76.67. The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Clovis Oncology Inc. [CLVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $29 to $33. The new note on the price target was released on May 18, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $5, while SVB Leerink analysts kept a Underperform rating on CLVS stock.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.11, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 0.76.
CLVS Stock Performance Analysis:
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.24. With this latest performance, CLVS shares dropped by -8.00% in over the last four-week period, additionally sinking by -74.73% over the last 6 months – not to mention a drop of -88.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 36.90, with the RSI for the last a single of trading hit 41.36, and the three-weeks RSI is set at 36.42 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 1.4814, while it was recorded at 0.7194 for the last single week of trading, and 2.7139 for the last 200 days.
Insight into Clovis Oncology Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -148.09 and a Gross Margin at +73.90. Clovis Oncology Inc.’s Net Margin is presently recorded at -177.82.
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Clovis Oncology Inc. [CLVS] Insider Position Details
There are presently around $37 million, or 40.00% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: VANGUARD GROUP INC with ownership of 12,348,898, which is approximately 22.084% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 9,985,759 shares of the stock with an approximate value of $6.62 million in CLVS stocks shares; and PALO ALTO INVESTORS LP, currently with $2.97 million in CLVS stock with ownership of nearly 11.91% of the company’s market capitalization.
Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 82 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 11,643,418 shares. Additionally, 60 investors decreased positions by around 21,259,746 shares, while 39 investors held positions by with 23,540,265 shares. The mentioned changes placed institutional holdings at 56,443,429 shares, according to the latest SEC report filing. CLVS stock had 25 new institutional investments in for a total of 1,429,245 shares, while 24 institutional investors sold positions of 2,307,232 shares during the same period.